There are 2789 resources available
1488O - Cancer risk in individuals with intellectual disability
Presenter: Qianwei Liu
Session: Proffered Paper session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1669O_PR - Late effects, long-term problems, and unmet needs of cancer survivors
Presenter: Martina Schmidt
Session: Proffered Paper session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1558O - COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine
Presenter: Stephen Thomas
Session: Proffered Paper session - SARS-CoV-2 and cancer
Resources:
Abstract
Slides
Webcast
1559O - Efficacy and toxicity of BNT162b2 vaccine in cancer patients
Presenter: Ithai Waldhorn
Session: Proffered Paper session - SARS-CoV-2 and cancer
Resources:
Abstract
Slides
Webcast
1561O - The future of the oncology workforce since COVID-19: Results of the ESMO Resilience Task Force survey series
Presenter: Kok Haw Jonathan Lim
Session: Proffered Paper session - SARS-CoV-2 and cancer
Resources:
Abstract
Slides
Webcast
LBA58 - Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with relapsed advanced or metastatic chordoma, on behalf of the French Sarcoma Group (FSG) and Unicancer
Presenter: Florence Duffaud
Session: Proffered Paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
LBA59 - LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study
Presenter: Patricia Pautier
Session: Proffered Paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
1520O - REGISTRI: Regorafenib in first-line of KIT/PDGFR wild type advanced GIST: Capatalize the A Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial
Presenter: Javier Martin Broto
Session: Proffered Paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
1521O - A phase II biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, an ultra-rare cancer with highly life-threatening unmet medical needs (NCCH1806/MK004)
Presenter: Yuki Kojima
Session: Proffered Paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
Introduction by the chair
Presenter: Nicolas Girard
Session: Are we ready to consider chemotherapy + checkpoint inhibitor as the preferred option in the neoadjuvant setting?
Resources:
Slides
Webcast